Evidence map›Paper›PMID 35121783›Full record

ArticleScientific reports2022

A functionalized graphene oxide with improved cytocompatibility for stimuli-responsive co-delivery of curcumin and doxorubicin in cancer treatment.

Fatemeh Yaghoubi, Najmeh Sadat Hosseini Motlagh, Seyed Morteza Naghib, Fateme Haghiralsadat, Hossein Zarei Jaliani, Ali Moradi

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Fatemeh YaghoubiDepartment of Clinical Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.ORCID 0000-0001-7799-2106
Najmeh Sadat Hosseini MotlaghDepartment of Biomedical Engineering, Meybod University, Meybod, Iran.
Seyed Morteza NaghibNanotechnology Department, School of Advanced Technologies, Iran University of Science and Technology (IUST), P.O. Box 16846-13114, Tehran, Iran.
Fateme HaghiralsadatDepartment of Advanced Medical Sciences and Technologies, School of Paramedicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Hossein Zarei JalianiDepartment of Medical Biotechnology, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Ali MoradiDepartment of Clinical Biochemistry, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran. morady2008@gmail.com.ORCID 0000-0002-2103-2592
Shahid Sadoughi University of Medical Sciences and Health Services · IRIran University of Science and Technology · IRMofid University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nowadays, the usage of nanoparticles in various fields such as drug delivery, attracts the attention of many researchers in the treatment of cancers. Graphene oxide (GO) is one of the novel drug delivery systems which is used broadly owing to its unique features. In this survey, doxorubicin (DOX) was accompanied by natural medicine, curcumin (CUR), to diminish its side effects and enhance its efficiency. Cytotoxicity assay in human gastric cancer (AGS), prostate cancer (PC3), and ovarian cancer (A2780), was evaluated. Also, the uptake of DOX and CUR into cells, was assessed using a fluorescence microscope. Moreover, real-time PCR was applied for the evaluation of the expression of RB1 and CDK2 genes, which were involved in the cell cycle. In both separate and simultaneous forms, DOX and CUR were loaded with high efficiency and the release behavior of both drugs was pH-sensitive. The higher release rate was attained at pH 5.5 and 42 °C for DOX (80.23%) and CUR (13.06), respectively. The intensity of fluorescence in the free form of the drugs, was higher than the loaded form. In the same concentration, the free form of CUR and DOX were more toxic than the loaded form in all cell lines. Also, free drugs showed more impact on the expression of RB1 and CDK2 genes. Co-delivery of CUR and DOX into the mentioned cell lines, was more effective than the free form of CUR and DOX due to its lower toxicity to normal cells.

Indexed as

Drug CarriersStimuli Responsive PolymersAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorCell SurvivalCurcuminCyclin-Dependent Kinase 2DoxorubicinDrug CompoundingDrug LiberationFemaleGraphiteHumansHydrogen-Ion ConcentrationKineticsMaleCDK2 protein, humanCurcuminCyclin-Dependent Kinase 2DoxorubicinDrug Carriersgraphene oxideGraphiteRB1 protein, humanRetinoblastoma Binding ProteinsStimuli Responsive PolymersUbiquitin-Protein Ligases

Identifiers

PMID35121783
PMCPMC8816945
OpenAlexW4210495219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.